Patents by Inventor Hidetoshi Tahara
Hidetoshi Tahara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926323Abstract: A vehicle controller includes: an engine controller configured to perform an IS control upon satisfaction of a predetermined stop condition and an engine restart control upon satisfaction of a predetermined restart condition; an HDC controller configured to perform, when the vehicle is traveling on a downhill road and a deceleration request according to an HDC control occurs, a target vehicle speed-based deceleration irrespective of brake operations by the driver; and an information acquisition part configured to acquire progress status information related to the engine restart control and including information on initiation and completion thereof.Type: GrantFiled: December 1, 2021Date of Patent: March 12, 2024Assignee: HONDA MOTOR CO., LTD.Inventors: Takahito Yoshida, Yoshinari Sugita, Rei Okubo, Hidetoshi Kobori, Shumpei Tahara, Shun Igarashi, Takuya Sato, Takayuki Matsuyoshi
-
Publication number: 20230167504Abstract: The present invention aims at providing a method of assisting the detection of pancreatic cancer with high accuracy.Type: ApplicationFiled: December 13, 2018Publication date: June 1, 2023Applicant: HIROSHIMA UNIVERSITYInventor: Hidetoshi TAHARA
-
Publication number: 20230160010Abstract: Disclosed is a method of assisting the detection of Alzheimer's disease, assisting in highly accurate detection of Alzheimer's disease. In the method of assisting the detection of Alzheimer's disease, the abundance of at least one of miRNAs or the like contained in a test sample isolated from a living body, whose nucleotide sequence is represented by any one of SEQ ID NOs: 1 to 85, is used as an index. A higher abundance of at least one of the miRNAs or the like whose nucleotide sequence is represented by any one of SEQ ID NOs: 1 to 22 and 66 to 71 than that of healthy subjects or a lower abundance of at least one of the miRNAs or the like whose nucleotide sequence is represented by any one of SEQ ID NOs: 23 to 65 and 72 to 85 than that of healthy subjects indicates a higher likelihood of having Alzheimer's disease.Type: ApplicationFiled: December 14, 2018Publication date: May 25, 2023Applicant: HIROSHIMA UNIVERSITYInventor: Hidetoshi TAHARA
-
Publication number: 20220218733Abstract: The object of the present invention is to find a pharmaceutical having strong cancer therapeutic effect. The present invention provides a pharmaceutical composition for cancer therapy comprising a transcription or processing product of a gene encoding a miRNA, wherein said miRNA is one or more miRNAs selected from the group consisting of miR-3140, miR-137, miR-631, and miR-657, pharmaceutical composition.Type: ApplicationFiled: March 15, 2022Publication date: July 14, 2022Inventors: Hidetoshi Tahara, Masaki Kinehara, Yuki Yamamoto
-
Publication number: 20220202848Abstract: The object of the present invention is to find a pharmaceutical having strong cancer therapeutic effect. The present invention provides a pharmaceutical composition for cancer therapy comprising a transcription or processing product of a gene encoding a miRNA, wherein said miRNA is one or more miRNAs selected from the group consisting of miR-3140, miR-137, miR-631, and miR-657, pharmaceutical composition.Type: ApplicationFiled: March 15, 2022Publication date: June 30, 2022Inventors: Hidetoshi Tahara, Masaki Kinehara, Yuki Yamamoto
-
Patent number: 11311568Abstract: The object of the present invention is to find a pharmaceutical having strong cancer therapeutic effect. The present invention provides a pharmaceutical composition for cancer therapy comprising a transcription or processing product of a gene encoding a miRNA, wherein said miRNA is one or more miRNAs selected from the group consisting of miR-3140, miR-137, miR-631, and miR-657, pharmaceutical composition.Type: GrantFiled: November 6, 2018Date of Patent: April 26, 2022Assignee: PURMX THERAPEUTICS, INC.Inventors: Hidetoshi Tahara, Masaki Kinehara, Yuki Yamamoto
-
Publication number: 20210079478Abstract: Disclosed is a method of assisting the detection of breast cancer, assisting in highly accurate detection of breast cancer. In the method of assisting the detection of breast cancer, the abundance of at least one of miRNAs, isomiRs, precursor miRNAs, or transfer RNA fragments contained in a test sample isolated from a living body and having a specific nucleotide sequence is used as an index. A higher abundance of at least one of the miRNAs or the like whose nucleotide sequence is represented by any one of, for example, SEQ ID NOs: 1 to 19, 27, 28, and 34 to 51 than that of healthy subjects or a lower abundance of at least one of the miRNAs or the like whose nucleotide sequence is represented by any one of, for example, SEQ ID NOs: 20 to 26, 29 to 33, and 52 to 54 than that of healthy subjects indicates a higher likelihood of having breast cancer.Type: ApplicationFiled: December 13, 2018Publication date: March 18, 2021Applicant: HIROSHIMA UNIVERSITYInventors: Hidetoshi TAHARA, Takahiro OCHIYA
-
Publication number: 20210071259Abstract: The present invention aims at providing a method of assisting the detection of head and neck cancer with high accuracy. The present invention provides a method of assisting the detection of head and neck cancer, which includes using as an index the abundance of at least one of miRNAs, isoform miRNAs (isomiRs), precursor miRNAs, transfer RNA fragments (tRFs), or non-coding RNA fragments (LincRNAs or MiscRNAs) contained in a test sample isolated from a living body.Type: ApplicationFiled: December 13, 2018Publication date: March 11, 2021Applicant: HIROSHIMA UNIVERSITYInventors: Hidetoshi TAHARA, Makoto TAHARA
-
Publication number: 20210024455Abstract: The compound according to the present invention is a compound represented by the following chemical formula: wherein, in the above-described chemical formula, R1 is oxygen or sulfur, and R2 to R6 are each independently selected from hydrogen, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, an acyl group having 1 to 6 carbon atoms and a nitro group.Type: ApplicationFiled: March 14, 2019Publication date: January 28, 2021Inventors: Hidetoshi TAHARA, Yoshitomo SHIROMA, Kei TAKEDA, Michiko SASAKI
-
Publication number: 20200386771Abstract: Provided are a novel method of evaluating an aging condition, a method of presenting information, and a method of screening for a substance capable of improving or preventing an aging condition. A method of evaluating an aging condition of a subject includes the step of: comparing a value from the subject of either of the amount of extracellular vesicles including exosomes in serum, the amount of advanced glycation end products of surface proteins on the extracellular vesicles, or parameters based on the amounts with a correlation criterion, the correlation criterion with the aging condition being pre-determined.Type: ApplicationFiled: November 13, 2018Publication date: December 10, 2020Inventors: Kaen Kan, Yukie Nishiyama, Mariko Ikuo, Hidetoshi Tahara
-
Publication number: 20200332361Abstract: Disclosed is a method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the method for assisting the highly accurate detection of Alzheimer's disease or mild cognitive impairment. In the method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the amount of at least one miRNA selected from miR-122, miR-144, let-7f, miR-128-3p and miR-107 contained in a test sample separated from a living body is used as an indicator. A larger amount of miR-122 than that in a healthy individual, or a smaller amount of at least one miRNA selected from miR-144, let-7f, miR-128-3p and miR-107 than that in a healthy individual is indicative that the living body is more likely to have developed Alzheimer's disease or mild cognitive impairment.Type: ApplicationFiled: July 2, 2020Publication date: October 22, 2020Applicant: HIROSHIMA UNIVERSITYInventors: Hidetoshi TAHARA, Masayasu MATSUMOTO, Yu NINOSE
-
Publication number: 20200254001Abstract: The object of the present invention is to find a pharmaceutical having strong cancer therapeutic effect. The present invention provides a pharmaceutical composition for cancer therapy comprising a transcription or processing product of a gene encoding a miRNA, wherein said miRNA is one or more miRNAs selected from the group consisting of miR-3140, miR-137, miR-631, and miR-657, pharmaceutical composition.Type: ApplicationFiled: November 6, 2018Publication date: August 13, 2020Inventors: Hidetoshi Tahara, Masaki Kinehara, Yuki Yamamoto
-
Patent number: 10738360Abstract: Disclosed is a method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the method for assisting the highly accurate detection of Alzheimer's disease or mild cognitive impairment. In the method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the amount of at least one miRNA selected from miR-122, miR-144, let-7f, miR-128-3p and miR-107 contained in a test sample separated from a living body is used as an indicator. A larger amount of miR-122 than that in a healthy individual, or a smaller amount of at least one miRNA selected from miR-144, let-7f, miR-128-3p and miR-107 than that in a healthy individual is indicative that the living body is more likely to have developed Alzheimer's disease or mild cognitive impairment.Type: GrantFiled: March 11, 2016Date of Patent: August 11, 2020Assignee: HIROSHIMA UNIVERSITYInventors: Hidetoshi Tahara, Masayasu Matsumoto, Yu Ninose
-
Patent number: 9932627Abstract: A method of measuring the length of a G tail sequence, characterized by hybridizing the G tail of an nondenatured chromosomal DNA in a sample with a labeled DNA probe having a sequence complementary to the telomere repeat sequence, measuring chemiluminescence from the hybridized DNA probe, and determining the length of the G tail sequence from the measured value, and a kit used for use in such a method.Type: GrantFiled: January 30, 2012Date of Patent: April 3, 2018Assignee: HIROSHIMA UNIVERSITYInventors: Hidetoshi Tahara, Toshinori Ide
-
Publication number: 20180067132Abstract: Disclosed is a method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the method for assisting the highly accurate detection of Alzheimer's disease or mild cognitive impairment. In the method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the amount of at least one miRNA selected from miR-122, miR-144, let-7f, miR-128-3p and miR-107 contained in a test sample separated from a living body is used as an indicator. A larger amount of miR-122 than that in a healthy individual, or a smaller amount of at least one miRNA selected from miR-144, let-7f, miR-128-3p and miR-107 than that in a healthy individual is indicative that the living body is more likely to have developed Alzheimer's disease or mild cognitive impairment.Type: ApplicationFiled: March 11, 2016Publication date: March 8, 2018Applicant: HIROSHIMA UNIVERSITYInventors: Hidetoshi TAHARA, Masayasu MATSUMOTO, Yu NINOSE
-
Patent number: 9909190Abstract: Disclosed is the provision of a method for assisting the detection of pancreatic cancer, the method assisting the detection of pancreatic cancer with high accuracy. In the method for assisting the detection of pancreatic cancer, the amounts of (1) miR-122-5p and (2) at least one miRNA selected from the group consisting of miR-16-5p, miR-19b-3p and miR-25-3p, all of which are contained in a test sample separated from a living body, are used as indicators. A larger amount of miR-122-5p and a smaller amount of at least one miRNA selected from the group consisting of miR-16-5p, miR-19b-3p and miR-25-3p than those in a healthy individual indicates that the living body is more likely to have developed pancreatic cancer.Type: GrantFiled: March 3, 2015Date of Patent: March 6, 2018Assignee: HIROSHIMA UNIVERSITYInventors: Hidetoshi Tahara, Kozue Ikeda
-
Publication number: 20170073764Abstract: Disclosed is the provision of a method for assisting the detection of pancreatic cancer, the method assisting the detection of pancreatic cancer with high accuracy. In the method for assisting the detection of pancreatic cancer, the amounts of (1) miR-122-5p and (2) at least one miRNA selected from the group consisting of miR-16-5p, miR-19b-3p and miR-25-3p, all of which are contained in a test sample separated from a living body, are used as indicators. A larger amount of miR-122-5p and a smaller amount of at least one miRNA selected from the group consisting of miR-16-5p, miR-19b-3p and miR-25-3p than those in a healthy individual indicates that the living body is more likely to have developed pancreatic cancer.Type: ApplicationFiled: March 3, 2015Publication date: March 16, 2017Applicant: HIROSHIMA UNIVERSITYInventors: Hidetoshi TAHARA, Kozue IKEDA
-
Publication number: 20170044597Abstract: An object of the present invention is to provide a method of detecting a nucleic acid binding protein and a method of screening for a binding inhibitor or promoter for a nucleic acid binding protein. According to the present invention, there is provided a method of detecting binding between a nucleic acid and a nucleic acid binding protein, comprising determining the degree of structural change in a nucleic acid complex having at least two nucleic acid duplex moieties.Type: ApplicationFiled: August 23, 2016Publication date: February 16, 2017Applicant: Hiroshima UniversityInventors: Hidetoshi TAHARA, Toru MIYAGI
-
Patent number: 9222089Abstract: The present invention aims to elucidate a miRNA involved in cellular senescence and to provide a method of use thereof. The senescence marker of the present invention comprises a gene transcript of miR-22. Further, the method for evaluating a senescence inhibitor of the present invention comprises the step of measuring the expression level of a gene transcript of miR-22 in a sample in the presence of a test compound and in the absence of the test compound; and the step of comparing the expression level of the gene transcript of miR-22 in the sample in the presence of the test compound with the expression level of the gene transcript of miR-22 in the sample in the absence of the test compound. Further, the cancer inhibitor of the present invention comprises as an effective component a gene transcript of miR-22, which cancer inhibitor promotes cellular senescence and inhibits invasion and/or metastasis of cancer.Type: GrantFiled: November 26, 2013Date of Patent: December 29, 2015Assignee: HIROSHIMA UNIVERSITYInventor: Hidetoshi Tahara
-
Publication number: 20140088173Abstract: The present invention aims to elucidate a miRNA involved in cellular senescence and to provide a method of use thereof. The senescence marker of the present invention comprises a gene transcript of miR-22. Further, the method for evaluating a senescence inhibitor of the present invention comprises the step of measuring the expression level of a gene transcript of miR-22 in a sample in the presence of a test compound and in the absence of the test compound; and the step of comparing the expression level of the gene transcript of miR-22 in the sample in the presence of the test compound with the expression level of the gene transcript of miR-22 in the sample in the absence of the test compound. Further, the cancer inhibitor of the present invention comprises as an effective component a gene transcript of miR-22, which cancer inhibitor promotes cellular senescence and inhibits invasion and/or metastasis of cancer.Type: ApplicationFiled: November 26, 2013Publication date: March 27, 2014Applicant: Hiroshima UniversityInventor: Hidetoshi TAHARA